A
Abscess 97
Activation-associated protein-1 664
Active bacterial core surveillance 373
Adaptive immune system 23
Adaptive immunity 4t
Adenocarcinoma in situ 451
Adhesin-based vaccine 591
Adolescent travellers, vaccines for 688t
Adolescent vaccination 677
Adult polio vaccination 212
Adverse drug reactions 95
Adverse effects following immunization 527
Aerosol infection 390
Agammaglobulinemia 298
Alanine aminotransferase 600
Allergic disorders, vaccines against 635
Alleviate pain 48
Alpha-synuclein 650
Ambiguous vaccine-derived poliovirus 203
Amino acids 7
Anaphylaxis 453
Anesthesia, superficial 48
Angiotensin-converting enzyme 2 560
Animal exposure, management of 391t
Anti-cyclic citrullinated peptide 651
Anti-inflammatory response 234
Antiretroviral therapy 191
Anti-tetanus prophylaxis 392
Antitubercular therapy 181
Anti-Vaccination Society 169
Anxiety-related reaction 97
Apical membrane antigen-1 vaccines 513
Aseptic meningitis 275t
Aspiration 50
Asplenia, functional 86
Asthma 521
Atypical measles 259
Autoimmune diseases 650
Autopsy, conduction 99
Auxiliary nurse midwives 95
Avian influenza 464
AYUSH doctor 155
B
B cells 5
Bacillus calmette-guérin 12, 26, 43, 46, 59, 60, 82, 105, 111–113, 161, 162, 178, 183–186, 189, 190, 192, 194, 565, 687, 692, 724, 730
adenitis, management of 182b
immunization 193
role of 563
scar 180f
status of 177
strains 194
characteristics of 177
effects of 184
Bacterial colonization 11
Bacterial meningitis 68
Basic reproductive number 31
Basic transmission cycle 406
Bat-infested caves 390
B-cell lymphoma 643
Bell's palsy 219
Bioterrorism 215
Bleeding disorders 90
Blindness 259
B-mannosylceramide 662
Bone marrow plasma cells 471
Booster doses 20
Bovine spongiform encephalopathy 134
C
Calmette-guérin and rubella 51
Campaign vaccination 429
Cancer immune therapeutics 634
Candidate Shigella vaccines 593
Candidate vaccine, subunit 593
Capsular polysaccharide 483
Cell culture rabies vaccines 394
Cell-based flu vaccine production 468
Cellular immune responses 657
Cellular immunity 657
Central Drugs Standard Control Organization 129
Cervarix 452t
Cervical intraepithelial neoplasia 2 448
biology of 617
development, vaccines for 624
fever
diagnosis of 621
treatment for 622
phylogenetic 618
tree of 618f
prevention of 623
role of 623
status of 624
Child and adolescent immunization schedule 79f
Childhood diarrhea 588b
Childhood vaccination schedule 269
Chimeric gene 639
Chimeric universal influenza vaccine 470
Chimpanzee adenovirus 602
Chinese vaccines, efficacy of 420
Chronic diseases 89
Clostridium perfringens 588
Cochlear implants 89
Cocooning 708
Cold spots 109
Cold-sensitive vaccines 110
Common mucosal immune system 664
Complex regional pain syndrome 453
Conjugate vaccines 10
Consumed milk 399
Control pertussis resurgence 247t
Cord antibodies levels 240f
COVID laboratory results, interpretation of 558t
Crohn's disease 650
Cryptosporidium parvum 589
Current immunization schedule 159
Cytokines 3
Cytosine phosphate guanine 578
D
Danger signals 5
Deadly disease 533
cases, distribution of 499f
disease, burden of 498
fever 640
development of 502
immunity against 501
Deoxyribonucleic acid 11, 25, 185–187, 281, 285, 287, 446, 468, 502, 561, 609, 629, 630, 630f, 631, 633, 635, 639
action of 631f
Dermonecrotic toxin 248
Diarrheal episodes 589
Dimethyldioctadecylammonium 662
Diphtheria, tetanus acellular, and pertussis 112
Disease estimation 29
Disease surveillance 62
District Immunization Officer 98
Dog transmit rabies 398
Domestic refrigerator, types of 108
E
Echovirus 9 219
Encapsulated bacteria 11
Endgame strategy 213
Engerix-b 289
Entamoeba 118
Enterotoxigenic escherichia coli 591
Enteroviral vaccines 582
Environmental mycobacteria 194
Environmental surveillance 74
Enzyme immunoassay 603
Epitope suppression 342
Equine rabies immunoglobulin 392
Equipment cleaners, types of 285
Ethics Committee, responsibilities of 132
European Medicines Agency 515
F
Facial paralysis 219
Families vaccine hesitant 169
Fever, low-grade 169
Fine-needle aspiration cytology 181
Fluorescent-antibody-to-membrane-antigen 313
Furious rabies 390
G
Gardasil 452t
General vaccination 1
Genetic Engineering Approval Committee 134
Genetic vaccines 629
Genital warts 451
Germinal centers 6
Glatiramer acetate 650
Glutamic acid dehydrogenase 651
Glycoconjugate vaccines 11
Glycoprotein B vaccine 579
Good clinical practice guidelines 132
Good manufacturing practice 417
Granulocyte-macrophage colony-stimulating factor 649
H
H1N1 304
H3N2 475
Haemophilus B conjugate 358
Hansenula polymorpha 458
Heat sensitive 111
Heat shock proteins 661
Helicobacter pylori 659
Hemagglutinin 462
Hematopoietic stem cell transplant 85
Hemolytic uremic syndrome 591
Heparan sulfate proteoglycans 449
prevention of 89
vaccination 309
inactivated 308
live 306
live attenuated 305
side effects of 307
infection 308
vaccines 305t
Hepatitis B 12, 15, 16, 22, 43, 68, 76, 105, 111–113, 152, 161, 165, 281, 285, 294, 498, 519, 679, 702, 703, 711, 724
birth dose 301
carriers 309
core 287
antibody 287
antigen 287
during pregnancy 707
immune globulin 713
role of 298
infectivity of 711
laboratory nomenclature 287t
panel results 286
prevention of 89
schedule for 294
signs of 284
symptoms of 284
adverse effects of 291
against 45
dose of 292
efficacy of 290
monovalent 293
single antigen 296
types of 288
core protein 584
infection, transmission of 282
maternal 288
prevalence of 281
role of 298
Hepatitis E 703
chronic 594
infection, prevalence of 594
vaccines 594
virus 594
combination vaccine of 597
components of 595
infection 594
Heterologous immune 27
Hip dysplasia 54
Hodgkin disease 370
Human coronavirus 563
Human cytomegalovirus 578
Human enterovirus 582
Human immunodeficiency virus 35, 97, 190, 191, 201, 206, 262, 329, 366, 380, 441, 454, 477, 489, 553, 559, 568, 568f, 569, 601, 605, 643, 657
biology of 568
development of 570
Human interleukin, recombinant 578
Human papillomavirus 14, 43, 84, 161, 446–450, 519, 576, 585, 652, 659, 678, 687, 692, 702, 704, 730
diseases 454
infection 448
vaccination 455
during pregnancy 704
protection after 459
Human rabies immunoglobulin 392
Human-to-human transmission 406
Humoral immunity 657
Hyperimmunoglobulins 54
Hyperventilation 97
Hypocalcemic seizures 252
Hypoglycaemia, severe 185
I
Ibuprofen 22
Ideal adjuvant, features of 657
Idiopathic thrombocytopenic purpura 326
Immune globulin 310
Immune memory 23
adverse effect of 75
after pregnancy 702t
anxiety-related reaction 94
before pregnancy 702t
before travel 691
practices 264
program 105
purpose of 39
record 156
regular 155
Immunized child 161
Immunizing pregnant women 90
Immunocompromised children 298
Immunocompromised conditions, types of 77
Immunodeficiency, severe combined 441
Immunosuppressive agents, categories of 81
Inconsolable crying 250
Infant antibodies 700f
Infection and prevention of disease, prevention of 550
Influence vaccine hesitancy 168
victoria lineage 466
complications of 463
intranasal 12
surveillance 464
symptoms of 463
varicella and zoster infection 78
virosomes 305
types of 462
Injectable polio 156
Innate cells 24
Integrated vector management, role of 623
Invasive bacterial infections surveillance 356
Invasive cervical carcinoma 448
Ipsilateral inguinal lymphadenopathy 192
Isothermic cold boxes 114
J
Japanese B encephalitis 688
Japanese encephalitis vaccine 158, 414, 414b, 415t, 420, 429, 430, 431b, 681, 696, 697, 697b, 719, 729–731
cost-effective 430
current status of 414
inactivated 428b
live attenuated 414
new generation of 431
recombinant 432
types of 430b
use of 428b
Jeryl-Lynn strain 275
L
Lapsed immunization 91
Latent tuberculosis infection 549
Leishmaniasis 642
Leningrad-3 strain 275
Leukemia 328
Leukocyte migration inhibition test 179
Linked-epitope suppression 236
Lipoidal biocarriers 572
Lower respiratory infection, acute 541
Lymphocytic choriomeningitis virus 578
Lymphoid tissue, mucosa-associated 662
Lymphoreticular tissue, nasopharyngeal-associated 664
L-zagreb strain 275
M
Macrophages 3
Malaria 509
control and prevention 510
Elimination Program 509
elimination, technical strategy for 509
Policy Advisory Committee 515
transmission 512
Master cell bank 134
Measles vaccination 262
adverse reactions of 261
contraindications of 261
regular 260
schedule of 261
Menacwy vaccines 489
Meningitis 268
Meningococcal polysaccharide vaccine 482
Meningococcal recombinant protein vaccines 481
Meningococcal serogroup B vaccines 489
Meningococcal vaccination 487
Meningococci, types of 481
Meningococcus 693
Meningoencephalitis 219
Merozoite surface protein-1 vaccines 513
Metered-dose inhaler 330
Micro-ribonucleic acid 187
Middle ear infection 259
Miliary tuberculosis 177
Ministry of Health and Family Welfare 145
Moraxella catarrhalis 371
Mouse brain 414
Mucosal adjuvants 664
Multiepitope fusion vaccine 591
Multiple vaccines, administration of 56b
Multivalent combination vaccines 336
Muramyl dipeptide 665
Mutants matter 285
Mutational antigens 634
N
Nasal mucosa 3
Nasopharyngeal swabs 558
National Drug Regulatory Authority 101
National Immunization Technical Advisory Group 145
National Institute for Communicable Diseases 399
National Institute of Virology 67
National Institutes of Health 444
Neoantigens 648
Neomycin 48
Neonatal immune responses 16
Neonatal sepsis, severe 184
Nerve tissue vaccine 393
Neuraminidase 462
Neutrophils 3
New pertussis vaccines 247
New vaccine, approval of 136
Noninvasive pneumococcal disease 374
Nonlive vaccines 6
Nonsterile injection, causes of 97b
Nonsteroidal anti-inflammatory drugs 621
Nontuberculous mycobacteria 194
Norwalk virus 589
Novel antigen candidate vaccines 593
Novel oral polio vaccine type 2 220
Nucleic acid vaccines 560
Nucleocapsid protein 559
O
Onchocerca volvulus 664
Optimal immunization schedules 39
cessation 215
contraindications of 201
monovalent 200
side effects of 201
stockpiles 221
trivalent 199
types of 199
Oral rehydration solution 442
Oral sex 284
Orally administered vaccines 49
Orchitis 268
Organ transplants 390
Orthomyxoviridae virus 462
P
Pancreatitis 268
Paracetamol 22
Paralytic rabies 390
Parasitic infection 195
Paratope 7
Paratyphoid fevers 334f
Parenteral vaccines, administration of 49
Parkinson's disease 650
Passive neonatal immunity 703
Passively acquired immunity 119
Pathogen-associated molecular patterns 8
Pediatric dengue vaccines, development of 502
Penta vaccine, dose of 97
Pentamer protein complex 577
Pentameric complex 578
Pentameric vaccines, soluble 579
Pentavalent vaccine 162
Pentaxim 228
booster 54
disease 234
epidemiology of 224
resurgence 246
samples 71
toxin 248
toxoid 253
against 45
doses of 252
live attenuated 248
Pet dog, vaccinated 398
Peyer's patches 664
Phagocytic function disorders, primary 77
Pichia pastoris 458
Pivotal trials 423
Placental transfer, percentage of 703f
Plasma cells, long-lived 19
Pneumococcal pneumonia and mortality, burden of 365
campaign 212
eliminated 163
free status 212
global eradication of 214
like syndrome 219
outbreak simulation exercise 219
sabin 12
salk 12
transition 220
schedule 207t
status of 718
against 45
schedule 207
vaccination 206
Polyradiculitis 268
Polyribosylribitol phosphate-outer membrane protein 358
Population for vaccination 120
Positive rubella titer 272
Postexposure vaccination 712
Postpolio eradication strategy 214
Postural orthostatic tachycardia syndrome 453
Pre-erythrocytic vaccine 512
Pre-exposure vaccination, schedule of 395
Pregnant woman traveler 694
Preservatives, roles of 48
Pretransplant 85
Primary complement deficiency 77
Prophylactic B cell combined vaccines 602
Prophylactic paracetamol 23
Prophylactic T cell combined vaccines 602
Prostatic acid phosphatase 649
Pseudomonas aeruginosa 340
Psoriasis 650
Purified chick embryo cell vaccine 394
Purified formalin inactivated vaccine 615
Purified protein derivative 179
Purified vero cell rabies vaccine 394
R
higher risk for 391
monoclonal antibodies 392
period of 390
postexposure treatment 398
tissue culture vaccines 399
transmission of 389
types of 390
vaccinated against 695
vaccination 400
prophylaxis of 394
route of 401
virus 390
Rapid fluorescent focus inhibition test 399
Recombinant vaccines, live 572
Refrigerator, purpose-built 106f
Renal failure, chronic 370
Resistant pathogens, surveillance of 367
Respiratory infections, acute 464
Retinoblastoma 634
Rheumatic diseases, chronic 89
Rheumatoid arthritis 650
Roseola 259
gastroenteritis 435
infection 434
serotypes 441
guidelines for 443
adverse effects of 440
doses of 438
preterm babies receive 439
Rubini strain 275
S
Safe injection practices 48
Safe vaccine storage 109
Sclerosing panencephalitis, subacute 262
Seasonal flu vaccines 474f
Seizures 259
Sentinel and population-based surveillance 65f
Sentinel surveillance 64
Serious side effects 485
Seroconversion rates 349
Sexual transmission 282
Sexually transmitted diseases 447
Shigellosis 592
Sick child 58
Smallpox 35
Spirit test 400
Stem cell harvest 85
Strengthen polio 215
Streptomycin sulfate 48
Superfluous antigen, administration of 522
Swachh Bharat Abhiyan 335
Synthetic flu vaccines 468
Synthetic influenza vaccines 469
Synthetic peptide vaccines 584
T
Tetravalent dengue vaccines, live attenuated 503f
T-helper cell type 233
Thimerosal causes autism 278
Toll-like receptors 8
Towne vaccine 577
Towne-toledo chimera vaccines 577
Toxic shock syndrome 262
Tracheal cytotoxin 248
Trained immunity 185
Transverse myelitis 268
Twinrix™ vaccine 308t
U
United Nations International Children's Emergency Fund 146
United States Food and Drug Administration 523
Universal immunization 301
V
Vaccinating Healthcare professionals with flu vaccine, advantages of 714
contraindications to 486
dose and route of 527
epidemiology in 28
in adolescents 552
in adults 552
in infants 552
in special situations 75
instructions for 48
issues of 81
practice of 48
program 30
role of gender-neutral 451
administration of 44
adverse effects of 596
all-in-one 22
approval 137t
permission of 134
available 481
brands 91
candidates 505
carriers 115
characteristics 22
clinical development of 125
communication, reframing of 171
confidence 102
conjugate 359
contents in 527
current status of 597
delivery, methods of 536
derived polio viruses 163
roadmap of 124t
and schedule of 595
estimates 419t
egg-based 467
egg-derived 468
failure 290
causes of 314
formation of 596
handling of 58
communication 171b
spectrum 168f
types of 167
immunogenicity 30
role in 8
inactivated 8
induced immunity, correlates of 12t
interchangeably 455
licensing of 124
lightsensitive 111
like particles 470
manufacturing 129
maternal 700
newer generations of 507
non-live 83t
performance of 6
poxvirus-based 432
product-related reaction 94
protection of 596
quality defect-related reaction 94
reaction, type of 97
refrigerator 110
responses, effectors of 11
safety testing of 126f
schedules 158
sensitivities 112t
side effects of 313
simultaneous 519
single-antigen 296
domestic refrigerator for 107f
equipment 105
subunit 560
third-generation 629
transmission-blocking 514
combination 519
inactivated 304
use to store 108
vaccination schedule for nonlive 17
vectored 579
vial monitor 273
stage of 201
with humoral immune response 602
Vaccinia ankara virus, modified 653
Venous thromboembolism 453
Verbal autopsy 99
Vertical transmission 282
VI-CPS vaccines, limitations of 338b
Viral infections 35
Viral pandemics 25
Virosomes 665
Vomiting 97
Vomits dose 439
Vulvar intraepithelial neoplasia 451
W
Whole virus vaccines 560
Whole-cell cholera vaccine 494
Whole-limb swelling 240
Whooping cough 101
Wild virus 577
Working cell bank 134